The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
Michelle Wilson
No relevant relationships to disclose
Neesha C. Dhani
No relevant relationships to disclose
Hal W. Hirte
No relevant relationships to disclose
Stephen Welch
No relevant relationships to disclose
Helen Steed
No relevant relationships to disclose
Lainie P. Martin
No relevant relationships to disclose
Stephanie Lheureux
No relevant relationships to disclose
Cristina Martin-Lorente
No relevant relationships to disclose
Helen Mackay
No relevant relationships to disclose
Marcus O. Butler
No relevant relationships to disclose
Lisa Wang
No relevant relationships to disclose
Judy Quintos
No relevant relationships to disclose
Katie Allen
No relevant relationships to disclose
Lynda Roman
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Amit M. Oza
No relevant relationships to disclose